Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
發表在NEJM上, 又是一篇關於DPP-4 inhibitor糖尿病用藥的討論
大概是之前Rosiglitazone的前車之鑑, 現在糖尿病的藥物都不停的探討著是否會增加心血管疾病機會
這項研究: Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial